DBV Technologies Q3 net loss $17.3M; cash $213M; VITESSE Phase 3 delayed by clinical hold

DBV Technologies S.A.

2022-Q3 EPS reported -$0.79 revenue$6,148,000

Q3 net loss of $17.3M ($0.18 per share); nine-month net loss $57.0M ($0.79 per share).
Cash and cash equivalents $212.7M as of Sept 30, 2022, up from $77.3M at Dec 31, 2021.
Operating expenses decreased 22% in Q3 and 26% in first nine months vs prior year.
Partial clinical hold on VITESSE Phase 3 study; first patient screen not expected by year-end 2022.
Cash used in operating activities fell 35% YoY; cost containment measures cited.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DBV Technologies S.A. reported the third quarter of 2022 results: net income $(17.3) million, EPS $(0.18).

Period: the third quarter of 2022
Net income: $(17.3) million
EPS: $(0.18)
Result: reported results

Exact text from the filing

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

DBV Technologies S.A. filing history →

Source: SEC EDGAR

accession 0001193125-22-277030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.